The micro-neutralization (MN) assay is a standard technique for measuring the infectivity of the influenza virus and the inhibition of virus replication. In this study, we present the protocol of an imaging-based MN assay to quantify the true antigenic relationships between viruses. Unlike typical plaque reduction assays that rely on visible plaques, this assay quantitates the entire infected cell population of each well. The protocol matches the virus type or subtype with the selection of cell lines to achieve maximum infectivity, which enhances sample contrast during imaging and image processing. The introduction of quantitative titration defines the amount of input viruses of neutralization and enables the results from different experiments to be comparable. The imaging setup with a flatbed scanner and free downloadable software makes the approach high throughput, cost effective, user friendly, and easy to deploy in most laboratories. Our study demonstrates that the improved MN assay works well with the current circulating influenza A(H1N1)pdm09, A(H3N2), and B viruses, without being significantly influenced by amino acid substitutions in the neuraminidase (NA) of A(H3N2) viruses. It is particularly useful for the characterization of viruses that either grow to low HA titer and/or undergo an abortive infection resulting in an inability to form plaques in cultured cells.
Introduction
Micro-neutralization (MN) assays are used in virology for the quantitation of neutralizing antibodies and of antiviral activities. As an alternative of hemagglutination inhibition (HI) assays, MN assays can overcome non-antigenic effects influenced by the affinity changes of receptor-binding in influenza viruses, which can complicate the interpretation of HI results 1, 2, 3 . Until recently, most MN assays were based on cytopathic effects (CPE) or enzyme-linked immunosorbent assays (ELISA) 4, 5 . MN assays based on focus and plaque reduction were developed in 1990 6, 7, 8 . Plaque reduction assays rely on counting visible plaques to quantify infectivity. However, visual counts only cover large plaques that are resolvable by human eyes, even though the majority of plaques are small and invisible for many current circulating viruses. This incomplete coverage can cause significant variation among examiners and between experiments, leading to incomparable results. It is also impossible to use the method when some viruses show abortive infection of single cells or very small plaques.
The poor counting resolution can be improved by the introduction of an imaging-based protocol. With advances in technology, optical microscopy and high-throughput well-plate readers can provide accurate means to count the infected cells 9 . Under a trans-illuminated microscope, infected cells tagged with certain markers may be visualized by their absorption or fluorescence contrast in sub-cellular resolution. A sample can then be analyzed on a computer screen.
Unfortunately, due to the limitation in the field of view, more than a hundred tiled images are required to cover a single well. Analyzing a plate with 96 wells would require the imaging and processing of about ten thousand images. Such a laborious process is time consuming and expensive, and the resolution gained is in general unnecessary for routine characterization of viral infections. Laboratories with a limited budget may find that the approach built around a flatbed scanner provides a cost-effective, high-throughput alternative.
In this paper, we describe an improved plaque reduction MN assay that is suitable for the antigenic characterization of a large number of viruses and for quantitatively measuring antiviral activities and neutralization antibodies. The assay has several advantages: firstly, it is an imagingbased assay that is able to measure virus infections on the cellular level, regardless of plaque size. Counting the total infected cell population (ICP) within a well greatly increases the detection sensitivity, making it possible to characterize the viruses with low infectivity. Secondly, a more accurate quantitative titration is introduced prior to neutralization to determine the amount of input virus. The quantitative input virus significantly reduces the variation between different experiments and makes the results more comparable between laboratories. Thirdly, neutralization titers can be determined directly by analyzing images, making the quantitation fast and user-friendly. Finally, the protocol provides a cost-effective and high-throughput alternative with the required resolution and accuracy. The quantitation is based on a flatbed scanner and free data processing software. The whole setup has a small footprint and is deployable in most laboratories. Figure 1 ), to duplicated wells (Columns 9 and 10 in Figure 1 ) of a 96-well plate. 6. Place the plate at 37 °C for 2-3 hr to allow the virus to infect the cells.
Virus Titration
NOTE: A 2 to 3 hr incubation is necessary to ensure that the viruses in the inoculum have enough time to reach the monolayer. 7. Prepare the overlay (10 ml/plate) NOTE: The overlay consists of 5 ml of 2x DMEM, Trypsin (2 µg/ml final concentration), 20 µl of 1 mg/ml stock, and 5 ml of cellulose cotton linters (see the Materials List). 8. Remove the inoculum. 9. Add the overlay (200 µl to each well). Incubate overnight at 37 °C, UNDISTURBED. NOTE: The virus budding takes place after approximately 4 hr, so it is important that the plate is not disturbed after this time. 10. Aspirate the overlay from the wells. 11. Add ice-cold 4% paraformaldehyde in PBS A (200 µl/well). Place them at 4 °C for 30 min or at room temperature for 20 min.
NOTE: PBS A is natural-pH phosphate-buffered saline with 10 g of NaCl, 0.25 g of KCl, 1.437 g of Na 2 HPO 4 , 0.25 g of KH 2 PO 4 , and 1 L of distilled water (see the Materials List). NOTE: Paraformaldehyde is harmful when inhaled and can cause burns if swallowed. There is also limited evidence of a carcinogenic effect, and it may cause sensitization after skin contact. 12. Aspirate the paraformaldehyde and wash the plates twice with PBS A (200 µl/well). 13. Store the plates in PBS A at 4 °C for future use, or carry on with the following steps. 14. Add permeabilization buffer (100 µl/well). Leave it at room temperature for 30 min. Alternately, wash it 3 times without incubation using 300 µl per well. 18. Add 50 µl of the second antibody, goat anti-mouse IgG (H+L) HRP conjugate (1:1,000 in ELISA Buffer), per well. Incubate it at room temperature for 1 hr, with shaking. 19. Wash it 3 times as described in step 1.17. 20. Add the substrate (50 µl/well). Incubate it at room temperature for 30 min or until the development of a blue color is clearly visible. 21. To stop the reaction, wash the plate twice with 200 µl of distilled water per well, incubating at room temperature for 2 -3 min between the washes.
1. Place a well plate in the scanning area of a flatbed scanner, as shown in Figure 2a . Use the L-shape position limit to ensure an optimum and repeatable imaging location. NOTE: It is possible to image two well plates in one scan. 2. Scan an image. NOTE: The settings are shown in Table 2 . 3. Run the "Wellplate Reader" software to calculate the required virus concentration (Figure 3 ).
1. Click the "Load image" button to load an image. Slide the red bar in the histogram of the "Global Threshold" tab to adjust the sampling threshold. Click the "Update" button to examine the effect on the image. 2. Tick the "Calculate Neutralization/Titration" box. Click the "Sampling" button to quantify the ICP. Click the "Save" button to save the sampling results when prompted. NOTE: After the sampling process, a new window called "Neutralization & Titration Calculation" appears automatically if the "Calculate Neutralization/Titration" box is ticked. 3. Load or input the well-plate definition map. Indicate the threshold (e.g., 30%) in "Titration: Optimal Virus Population (%)". Select the "Titration Process" tab to calculate the titration results. Check the titration results. Click the "Save & Close" button to save the titration results. NOTE: Refer to Supplementary S1 for more detailed instruction on the software. A copy of the bespoke software is available upon request. NOTE: Typically, the best virus dilution for the plaque-reduction assay yields around 50% (20-85%) ICP of total cells within each well 11 .
Virus Neutralization
NOTE: Calculate the number of plates required for the neutralization assay. Each plate can accommodate one virus and a number of antisera.
NOTE: Depending on the number of antisera and the number of duplicates, a well plate can be set up with the following flexibilities: (1) The serum dilution can be arranged along either row or a column (Figure 4) . Each serum should occupy a separate row or column. (2) The increment of serum dilution is flexible, but it should start with the highest serum concentration at the top-left corner of a plate. (3) The number of duplicates balances the number of antisera. More duplicates can help to smooth out experimental variations. (4) The number of the VC and the number of the cell control (CC) duplicates are flexible, but they should also be in separate rows or columns. It is expected that the number of VC duplicates is significantly greater than that of the antisera.
Representative Results
Following the above procedures, we present some results from recent antigenic characterization experiments. The titration setup was designed to examine eight input viruses, with double duplicates for each dilution. The viral dilutions were tested between 1.0 Figure 5d ). The virus dilutions that produced 30% of ICP saturation were chosen as the input virus dilution for neutralization ( Table 3) . . The background ICP from uninfected cell controls was subtracted during the normalization. The neutralization titers were determined as the reciprocals of the antiserum dilutions corresponding to 50% ICP reduction ( Table 4) . Linear interpolation was used to estimate titers falling between two adjacent serum dilutions. 
Discussion
In this study, we described an imaging-based MN assay to quantify the true antigenic relationships between viruses. Compared with other plaque-reduction assays, the method emphasizes measuring the ICP of an entire well, ensuring the complete coverage of the infective population. Its independence of plaque formation also widens the application of the assay to viruses that can form mainly invisible small plaques or that can only manage single-cell infection. Therefore, the assay is capable of examining more viruses and the effects of a wider range of antibodies than HI, and it helps to more comprehensively reflect the antigenic similarities or differences between viruses .
The protocol matched the virus type or subtype with the selection of cell lines that gave the strongest infection, which greatly enhanced the imaging signal. Experimental variation was smoothed with the design of duplicates that balanced with the number of tested antisera. Uncertainties can also come from the image quality, which is mainly influenced by the imaging device. A decent color flatbed scanner can significantly improve the image contrast and reduce the noise. The amount of input virus in the neutralization must be quantitatively determined in advance from the corresponding titration while the viruses still maintain a similar status. During neutralization, the antiserum response to an infection is normalized against the difference between the reference virus (VC) and the background level (CC). Accurate measurements of VC and CC are essential to a neutralization experiment. More duplicates are recommended (eight duplicates were used in the Representative Results). Finally, understanding the software is vital to the success of an experiment. The software has been tested for routine virus characterization in the WHO Influenza Centre, UK for more than two years. Detailed instructions for dealing with various situations is provided in the Supplementary S1.
This MN assay is suitable for applications where the samples cover an extremely large field of view but only require moderate imaging resolution. The low cost and simple setup make the system readily available to most virology laboratories. The variation in measurements of the same sample was less than 3%, which roughly defines the uncertainty introduced during the scanning 11 . Such reproducibility is sufficient in many virological studies and can be further reduced by averaging images from multiple scans.
In conclusion, this study demonstrates a robust MN assay that can be routinely used in antigenic study and to support HI data in detailed analyses of currently-circulating influenza viruses, notably for the biannual selection of viruses for inclusion in human influenza vaccines.
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